Senesco Technologies Inc. (SNT) Moves Promising Drug toward Clinical Trial
Senesco Technologies Inc. secured additional financing to continue research into genetic technologies designed to deter apoptosis, or programmed cell death, in humans. This technology is applicable in many different diseases including cancer, glaucoma, and cardiovascular problems. The financing will come in three pieces and will total $705,000. The company will issue 783,332 shares of its common stock at $0.90 per share, and two separate warrant issues. The first warrant will grant the right to purchase up to 705,000 shares of common stock, at an exercise price of $0.01 per share, exercisable immediately. The balance of the warrants will grant the…